Clinical Course of Patients Treated for Advanced Ovarian Carcinoma without Surgical Intervention

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Eitan, Ram ^a   Krissi, Haim ^a   Levavi, Hanoch ^a   Sabah, Gad ^a   Peled, Yoav ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DISEASE COURSE; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 84873867390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055645     Document Type: Article

References (14)

1. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, et al. (2004) Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (Suppl 8): viii7-viii12.
2. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, et al. (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials- by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115: 1234-1244.
3. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, et al. (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: 974-979.
4. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, et al. (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107: 77-85.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ, (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259.
6. Bristow RE, Chi DS, (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103: 1070-1076.
7. Chambers JT, Chambers SK, Voynick IM, Schwartz PE, (1990) Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 37: 327-331.
8. Schwartz PE, (2002) Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 6: 585-596.
9. Vergote I, De Wever I, Tjalma W, van Gramberen M, Decloedt J, et al. (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71: 431-436.
10. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363: 943-953.
11. Ozols RF, (2005) Gemcitabine and carboplatin in second-line ovarian cancer. Semin Oncol 32(4Suppl 6): S4-S8.
12. Bookman MA, Greer BE, Ozols RF, (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 13: 735-740.
13. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43.
14. DeVita VT, Hellman S, Rosenberg SA (2001) Cancer: principles and practice of oncology. 6th edn. Philadelphia: Lippincott Williams & Wilkins. p. 1092.